Cover Image
市場調查報告書

Access Pharmaceuticals, Inc. - 產品平台分析

Access Pharmaceuticals, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 224597
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Access Pharmaceuticals, Inc. - 產品平台分析 Access Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日期: 2014年04月30日 內容資訊: 英文 34 Pages
簡介

Access Pharmaceuticals, Inc.正在開發癌症治療及癌症患者支持療法之劃期性藥物,獲得以美國為首,歐洲、中國、韓國等廣泛認証。

本報告提供Access Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Access Pharmaceuticals, Inc.的基本資料

Access Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Access Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Access Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Access Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Access Pharmaceuticals, Inc.:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Access Pharmaceuticals, Inc.:藥物簡介

  • AP-5346
  • CobaCyte Targeted Therapeutics For Oncology
  • CobOral hGH
  • CobOral Insulin
  • GLP-1
  • Oral Fertility Drugs
  • Prolindaun
  • RNAi Therapeutics

Access Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Access Pharmaceuticals, Inc.:最近的開發平台趨勢

Access Pharmaceuticals, Inc.:暫停中的計劃

Access Pharmaceuticals, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • Thiarabine

Access Pharmaceuticals, Inc.:企業發表

Access Pharmaceuticals, Inc.:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04801CDB

Global Markets Direct's, 'Access Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Access Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Access Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Access Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Access Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Access Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Access Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Access Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Access Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Access Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Access Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Access Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Access Pharmaceuticals, Inc. Snapshot
    • Access Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Access Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Access Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Access Pharmaceuticals, Inc. - Pipeline Products Glance
    • Access Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Access Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Access Pharmaceuticals, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Access Pharmaceuticals, Inc. - Drug Profiles
    • AP-5346
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CobaCyte Targeted Therapeutics For Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CobOral hGH
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CobOral Insulin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLP-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oral Fertility Drugs
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Prolindaun
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Therapeutics
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Access Pharmaceuticals, Inc. - Pipeline Analysis
    • Access Pharmaceuticals, Inc. - Pipeline Products by Target
    • Access Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Access Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Access Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Access Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Access Pharmaceuticals, Inc. - Dormant Projects
  • Access Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Thiarabine
  • Access Pharmaceuticals, Inc. - Company Statement
  • Access Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Access Pharmaceuticals, Inc., Key Information
  • Access Pharmaceuticals, Inc., Key Facts
  • Access Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • Access Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Access Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Access Pharmaceuticals, Inc. - Phase II, 2014
  • Access Pharmaceuticals, Inc. - Preclinical, 2014
  • Access Pharmaceuticals, Inc. - Unknown, 2014
  • Access Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • Access Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • Access Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • Access Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Access Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • Access Pharmaceuticals, Inc. - Dormant Developmental Projects,2014
  • Access Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014
  • Access Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Access Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • Access Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Access Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Access Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • Access Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Access Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Access Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top